Table 6 Additional areas of interest within mesothelioma immunotherapy
From: Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma
Outstanding areas of interest for immunotherapy in MPM | |
|---|---|
1 | Can we combine Tumor-Treating Fields (TTF) with checkpoint inhibitors? |
2 | How can we best stratify patients to checkpoint inhibitors? |
3 | Is there any utility for the use of PD-L1 expression as a biomarker to direct therapy? |
4 | Can we epigenetically prime MPM for checkpoint inhibitor therapy? |
5 | Can we use BAP1 status in immunotherapy of MPM? |
6 | Would targeting Toll Like Receptors (TLRs) along with checkpoint inhibitors prove beneficial? |
7 | What is the best way to monitor response to checkpoint inhibitors? |
8 | Is the cost prohibitive for the use of checkpoint inhibitors in the second-line/salvage setting? |